Because of this property, Erwinia asparaginase is indicated as a component of a multiagent chemotherapy regimen for the treatment patients with ALL who have developed potential hypersensitivity to l-asp derived from E. coli [6,12]. Here, ASPG is linked to acute lymphoblastic leukemia.